AINEWS
Your next prescription refill could be an AI decision.
Utah let an AI tool handle prescription renewals. Doctors are fighting back before other states copy the template.
Utah let an AI tool handle prescription renewals. Doctors are fighting back before other states copy the template.
For a routine prescription refill somewhere in Utah, the decision now goes through an AI tool called Doctronic instead of a clinician. A patient gets the refill, or doesn't, and the call is software's. Physicians are publicly asking for a way to override it.
The mechanism is a regulatory sandbox: a state-defined carve-out that lets software make a clinical decision the surrounding healthcare system would normally route through a licensed prescriber. On January 6, 2026, Utah's Department of Commerce designed that lane through a partnership with Doctronic (commerce.utah.gov), establishing the state's Office of Artificial Intelligence Policy as the operative regulatory authority. Utah became the architect of the carve-out, not a passive host.
The program is currently in Phase One, in which every AI-generated refill decision is reviewed by a licensed physician before being transmitted to a pharmacy (apnews.com). Doctronic has said it expects to transition to Phase Two, in which physicians would review prescribing decisions after the fact, making the software the primary decision-maker. The Associated Press picked up the story through its national wire on July 6, 2026 (apnews.com), and the syndicated version reached outlets including the Lowell Sun (lowellsun.com). The frame across all of them is the same: doctors are uneasy.
The wariness is grounded in clinical responsibility, not generic AI skepticism. The Utah Medical Licensing Board learned of the program's January launch from news reports. In meetings and in an April 20, 2026 letter signed by 11 of the board's members, the board called for the program to be halted immediately, citing the risks of automatically renewing medicines that can have side effects or drug interactions (kuer.org April 28). "Proceeding with this agreement without consulting the Medical Board potentially places Utah citizens at risk," the letter said. The Commerce Department rejected the board's call, saying the program would continue.
Dr. Alan Smith, a family physician who chairs the Utah Medical Licensing Board, has spoken publicly about the risks. He told KUER that his concerns are grounded in what he sees at six-month check-ins: "Many times when I see people after six months I find that their medical history or situation has changed. Just because something was prescribed before does not mean it's appropriate now." Smith said the board was not consulted before the program launched. "We were essentially told: 'Yes, this is going on. And no, you don't have a say in it.'" He said he worries the program will continue until patients are harmed. "I'm just very afraid that nothing's going to happen until we have some deaths," he said.
Dr. Eric Bressman, a physician at the University of Pennsylvania who studies AI in healthcare, is one of the named experts who has weighed in nationally on the Utah case. "We have crossed a threshold in terms of giving something that is not human a medical license, whether or not we want to call it that," he told the AP. Bressman and other experts say they are not opposed to AI prescribing but say it should have to meet the same rigorous standards — years of testing and training — that human doctors undergo before being licensed to practice medicine.
The regulatory jurisdiction is split. The FDA oversees AI that directly impacts medical care or decision-making, and some experts believe Doctronic has crossed the line into that territory. But the FDA has signaled a hands-off approach to AI prescribing software. State pharmacy boards and scope-of-practice law govern the actual act of prescribing, which is what allows Utah's Commerce Department sandbox to operate: the state can waive state-level rules, but the federal-state divide is the reason the FDA's posture matters (apnews.com). Daniel Aaron, a University of Utah Law associate professor who holds both a law degree and a medical degree and has co-authored a journal article on the program, told KUER: "This program has moved forward without the normal legal checks and guardrails, and that's extremely concerning. Neither the federal nor state checks that are protecting us, the consumers, are even being used."
Under the program, according to the Commerce Department press release, Doctronic is authorized to participate in prescription renewals for chronic conditions (commerce.utah.gov). What categories of medication or specific prescription types the sandbox covers beyond that characterization has not been publicly specified in the available sources. Doctronic has excluded what it describes as higher-risk prescriptions from the refill program; the April 28 KUER report noted that several medications were removed from the eligible list following safety concerns, including a drug for irregular heartbeats.
The partnership announcement dates to January 6, 2026; the physicians' public concerns date to meetings and April 2026, with the medical board's formal call to halt the program recorded in an April 20 letter. A second state clearing the same regulatory path would convert Utah's experiment into a template. Texas and Wyoming have also begun waiving rules for AI in healthcare, and bills based on a template from the Cicero Institute — a pro-AI think tank founded by Palantir co-founder Joe Lonsdale — have been introduced in Iowa, Idaho and elsewhere to formally license AI medical services.